CA2186867A1 - Methodes d'utilisation de chelates contenant du fer pour diminuer les atteintes dues aux radicaux libres chez les mammiferes - Google Patents

Methodes d'utilisation de chelates contenant du fer pour diminuer les atteintes dues aux radicaux libres chez les mammiferes

Info

Publication number
CA2186867A1
CA2186867A1 CA2186867A CA2186867A CA2186867A1 CA 2186867 A1 CA2186867 A1 CA 2186867A1 CA 2186867 A CA2186867 A CA 2186867A CA 2186867 A CA2186867 A CA 2186867A CA 2186867 A1 CA2186867 A1 CA 2186867A1
Authority
CA
Canada
Prior art keywords
mammals
free radical
radical damage
methods
chelating compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2186867A
Other languages
English (en)
Other versions
CA2186867C (fr
Inventor
Donald L. Bissett
Steven Alan Shaya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2186867A1 publication Critical patent/CA2186867A1/fr
Application granted granted Critical
Publication of CA2186867C publication Critical patent/CA2186867C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002186867A 1994-04-08 1995-03-06 Methodes d'utilisation de chelates contenant du fer pour diminuer les atteintes dues aux radicaux libres chez les mammiferes Expired - Fee Related CA2186867C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22494994A 1994-04-08 1994-04-08
US08/224,949 1994-04-08
PCT/US1995/002872 WO1995027485A1 (fr) 1994-04-08 1995-03-06 Methodes d'utilisation de chelates contenant du fer pour diminuer les atteintes dues aux radicaux libres chez les mammiferes

Publications (2)

Publication Number Publication Date
CA2186867A1 true CA2186867A1 (fr) 1995-10-19
CA2186867C CA2186867C (fr) 2000-12-12

Family

ID=22842898

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002186867A Expired - Fee Related CA2186867C (fr) 1994-04-08 1995-03-06 Methodes d'utilisation de chelates contenant du fer pour diminuer les atteintes dues aux radicaux libres chez les mammiferes

Country Status (4)

Country Link
EP (1) EP0754039A4 (fr)
JP (1) JP2001508755A (fr)
CA (1) CA2186867C (fr)
WO (1) WO1995027485A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2746015B1 (fr) * 1996-03-18 1998-04-24 Utilisation de l'octopirox comme agent depigmentant
US5922761A (en) * 1996-09-06 1999-07-13 Medinox, Inc. Methods for in vivo reduction of iron levels and compositions useful therefor
TWI234467B (en) 1997-06-04 2005-06-21 Univ Michigan Composition for inhibiting photoaging of skin
EP1013272A1 (fr) * 1998-12-23 2000-06-28 Biomedical Primate Research Centre (BPRC) Manipulation de l'activité d'une voie de production du radical oxyde d'azote pour le traitement de maladies liées à la présence de radicaux libres oxygénés
NL1012825C2 (nl) * 1999-08-13 2001-02-23 Faculteit Geneeskunde Universi Farmaceuticum voor de behandeling van virale infecties in het bijzonder van het humane immunodeficiency virus (HIV).
CN1376049A (zh) * 1999-08-24 2002-10-23 宝洁公司 通过局部施用含肟化合物的组合物增白角质组织的方法
ITMI20022447A1 (it) * 2002-11-19 2004-05-20 Carlo Ghisalberti Uso di piridinoni nel trattamento della purpura capillare ed affezioni cutanee correlate.
WO2005055931A2 (fr) * 2003-12-03 2005-06-23 University Of Medicine And Dentistry Of New Jersey Procede pour empecher la survie des cellules retrovirales et la formation des retrovirus infectieux
CN101679263B (zh) 2007-03-28 2014-01-15 阿普泰克斯科技公司 去铁酮的氟化衍生物
EP2268282B1 (fr) 2008-04-25 2014-10-29 Apotex Technologies Inc. Formulation liquide de défériprone de goût agréable
GEP20146008B (en) 2009-07-03 2014-01-10 Apotex Tech Inc Fluorinated derivatives of 3-hydroxypyridin-4-ones
KR20230004944A (ko) * 2016-08-05 2023-01-06 아브페로 파마슈티칼스, 인크. 금속-매개 상태를 치료하기 위한 투여 요법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3856315T2 (de) * 1987-10-22 1999-10-14 The Procter & Gamble Co. Chelatbildner enthaltende Lichtschutzmittel
ES2199214T3 (es) * 1990-04-26 2004-02-16 THE PROCTER &amp; GAMBLE COMPANY Composiciones quelantes que comprenden compuestos oxima.
WO1992016200A1 (fr) * 1991-03-20 1992-10-01 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Utilisation de derives d'acide hydroxamique pour l'inhibition de la replication virale

Also Published As

Publication number Publication date
CA2186867C (fr) 2000-12-12
JP2001508755A (ja) 2001-07-03
EP0754039A4 (fr) 2002-07-17
EP0754039A1 (fr) 1997-01-22
WO1995027485A1 (fr) 1995-10-19

Similar Documents

Publication Publication Date Title
CA2253593A1 (fr) Prevention et traitement du cancer colorectal par l&#39;acide 6-fluoro-ursodesoxycholique (6-fudca)
CA2140106A1 (fr) Methode de traitement des affections vasculaires hyperproliferatives
CA2186867A1 (fr) Methodes d&#39;utilisation de chelates contenant du fer pour diminuer les atteintes dues aux radicaux libres chez les mammiferes
TW271395B (fr)
MY123354A (en) 4&#34;-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
CA2002859A1 (fr) Methode de traitement d&#39;affections epitheliales
ZA948031B (en) Methods of inhibiting uterine fibroses
EP0422803A3 (fr) Dentifrice contenant un agent bactéricide cationique
EP0963756A3 (fr) Inhibition de l&#39;oxidation de LDL et de l&#39;athérosclérose
MY130555A (en) Super absorbent polymer composition
CA2001765A1 (fr) Chelants possedant une fonctionnalite d&#39;ortho-ligature et ses complexes
CA2091766A1 (fr) Accroissement de la concentration de glutathione au moyen de la glutamine
UA37311C2 (uk) Засіб для лікування статевої дисфункції і фармацевтичний препарат
EP0135189A3 (fr) Malonamides à utilisation pharmaceutique
ES8401928A1 (es) Procedimiento de obtencion de composiciones oftalmologicas.
WO1991015466A3 (fr) Agents chelateurs
IL69815A (en) Pharmaceutical compositions for the treatment of herpes 1 and a method of treatment of non-human warm-blooded animals against herpes 1
MX9503625A (es) Metodo para reducir el daño por radicales libres en celulas de mamiferos vivos.
MY133222A (en) Method of treating glaucoma and ischemic retinopathy
CA2090234A1 (fr) Methode permettant d&#39;obtenir un effet analgesique ameliore
EP0260790A3 (fr) Utilisation de la pinacidile dans le traitement de l&#39;incontinence
GB9009852D0 (en) Compositions of some therapeutic advantage prepared from a combination of an antiseptic with a sympathomimetic compound in the form of nose drops
FR2539826B1 (fr) Pieces de quincaillerie pour meuble et agencement en tole d&#39;acier protegee par un traitement de surface soit de protection soit decoratif
EP0400312A3 (fr) Procédé et composition pour le traitement d&#39;infections protozoiques avec un agent antibactérien
MX9701532A (es) Procedimiento para aumentar los niveles de testosterona.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed